438 related articles for article (PubMed ID: 18053608)
41. [Changes of plasma endothelin-1 and vascular endothelial growth factor in diabetic retinopathy and the clinical application value thereof].
Zhu H; Shi CH
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2837-9. PubMed ID: 18167288
[TBL] [Abstract][Full Text] [Related]
42. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema.
Shimada H; Akaza E; Yuzawa M; Kawashima M
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2953-5. PubMed ID: 19060271
[TBL] [Abstract][Full Text] [Related]
43. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines.
Funatsu H; Yamashita H; Mimura T; Noma H; Nakamura S; Hori S
Eye (Lond); 2007 Mar; 21(3):377-82. PubMed ID: 16410812
[TBL] [Abstract][Full Text] [Related]
44. Management of proliferative diabetic retinopathy.
Gündüz K; Bakri SJ
Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
[TBL] [Abstract][Full Text] [Related]
45. [Role of vascular endothelial growth factor in the development of diabetic retinopathy in patients with type 1 diabetes mellitus].
Ermakova NA; Syrodeeva ON; Antsiferov MB; Balatskaia NV; Krasnova LB
Vestn Oftalmol; 2008; 124(1):25-8. PubMed ID: 18318205
[TBL] [Abstract][Full Text] [Related]
46. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
[TBL] [Abstract][Full Text] [Related]
47. Expression of vascular endothelial growth factor in proliferative diabetic retinopathy.
Merlak M; Kovacević D; Balog T; Marotti T; Misljenović T; Mikulicić M; Dekaris I
Coll Antropol; 2008 Oct; 32 Suppl 2():39-43. PubMed ID: 19138004
[TBL] [Abstract][Full Text] [Related]
48. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients.
Funatsu H; Yamashita H; Noma H; Mimura T; Nakamura S; Sakata K; Hori S
Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):3-8. PubMed ID: 15258777
[TBL] [Abstract][Full Text] [Related]
49. Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy.
Ishida S; Shinoda K; Kawashima S; Oguchi Y; Okada Y; Ikeda E
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1649-56. PubMed ID: 10845581
[TBL] [Abstract][Full Text] [Related]
50. Monitoring ocular drug therapy by analysis of aqueous samples.
Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
[TBL] [Abstract][Full Text] [Related]
51. The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy.
Byon IS; Jeon HS; Kim HW; Lee SJ; Lee JE; Oum BS
Curr Eye Res; 2013 Jul; 38(7):774-80. PubMed ID: 23725216
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical analysis of cellular adhesion molecules (ICAM-1, VCAM-1) and VEGF in fibrovascular membranes of patients with proliferative diabetic retinopathy: preliminary study.
Khalfaoui T; Lizard G; Beltaief O; Colin D; Ben Hamida J; Errais K; Ammous I; Zbiba W; Tounsi L; Zhioua R; Anane R; Ouertani-Meddeb A
Pathol Biol (Paris); 2009; 57(7-8):513-7. PubMed ID: 18834676
[TBL] [Abstract][Full Text] [Related]
53. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
54. Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy.
Roldán-Pallarés M; Rollín R; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R
Retina; 2007 Feb; 27(2):222-35. PubMed ID: 17290206
[TBL] [Abstract][Full Text] [Related]
55. Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy.
Zheng Z; Chen H; Xu X; Li C; Gu Q
Exp Eye Res; 2007 Apr; 84(4):745-52. PubMed ID: 17303121
[TBL] [Abstract][Full Text] [Related]
56. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
[TBL] [Abstract][Full Text] [Related]
57. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.
Sonmez K; Drenser KA; Capone A; Trese MT
Ophthalmology; 2008 Jun; 115(6):1065-1070.e1. PubMed ID: 18031819
[TBL] [Abstract][Full Text] [Related]
58. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy.
Semeraro F; Cancarini A; Morescalchi F; Romano MR; dell'Omo R; Ruggeri G; Agnifili L; Costagliola C
Diabetes Metab; 2014 Dec; 40(6):445-51. PubMed ID: 24878492
[TBL] [Abstract][Full Text] [Related]
59. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy.
Sydorova M; Lee MS
Ophthalmic Res; 2005; 37(4):188-90. PubMed ID: 15990461
[TBL] [Abstract][Full Text] [Related]
60. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy.
Hernández C; Segura RM; Fonollosa A; Carrasco E; Francisco G; Simó R
Diabet Med; 2005 Jun; 22(6):719-22. PubMed ID: 15910622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
